Department of Vascular Surgery, Hopital Henri Mondor, Créteil, France.
Eur J Vasc Endovasc Surg. 2011 Sep;42(3):340-6. doi: 10.1016/j.ejvs.2011.04.033. Epub 2011 May 31.
Splanchnic and renal artery aneurysms (SRAAs) are uncommon but potentially life-threatening in case of rupture. Whether these aneurysms are best treated by open repair or endovascular intervention is unknown. The aim of this retrospective study is to report the results of open and endovascular repairs in two European institutions over a fifteen-year period. We have reviewed the available literature published over the 10 last years.
All patients with SRAAs diagnosed from 1995 to 2010 in St Marys Hospital (London, UK) and Henri Mondor Hospital (Créteil, France) were reviewed. Preoperative clinical and anatomical data, operative management and outcomes were recorded from the charts and analyzed.
40 patients with 51 SRAAs were identified. There were 21 males and 19 females with a mean age of 57 ± 14.9 years. The aneurysms locations were: 14 (27%) renal, 11 (22%) splenic, 7 (14%) celiac trunk, 7 (14%) superior mesenteric artery, 4 (8%) hepatic, 4 (8%) pancreaticoduodenal arcades, 3 (6%) left gastric and 1 (2%) gastroduodenal. 4 patients presented with a ruptured SRAA. 17 SRAAs in 16 patients were treated by open repair, 15 in 15 patients were treated endoluminally and 17 (mean diameter: 18 mm, range: 8-75 mm) were managed conservatively. One patient with metastatic pulmonary cancer with two mycotic aneurysms of the superior mesenteric artery (75 mm) and celiac trunk (15 mm) was palliated. After endovascular treatment, the immediate technical success rate was 100%. There was no significant difference between open repair and endovascular patients in terms of 30-day post-operative mortality rate and peri-operative complications. No in-hospital death occurred in patients treated electively. Postoperatively, four patients (1 ruptured and 3 elective) suffered non-lethal mild to severe complication in the open repair group, as compared with one in the endovascular group (p = .34). The mean length of stay was significantly higher after open repair as compared with endovascular repair (17 days, range: 8-56 days vs. 4 days, range: 2-6; p < .001). The mean follow-up time was 17.8 months (range: 0-143 months) after open repair, 15.8 months (range: 0-121 months) after endovascular treatment, and 24.8 (range: 3-64 months) for patient being managed conservatively. No late death related to the VAA occurred. In each group, 2 successful reoperations were deemed necessary. In the endovascular group, two patients presented a reperfusion of the aneurysmal sac at 6 and 24 months respectively.
No significant difference in term of 30-day mortality and post-operative complication rates could be identified between open repair and endovascular treatment in the present series. Endovascular treatment is a safe alternative to open repair but patients are exposed to the risk of aneurysmal reperfusion. This mandates careful long-term imaging follow up in patients treated endoluminally.
内脏和肾动脉动脉瘤(SRAAs)虽然少见,但在破裂时可能会危及生命。这些动脉瘤是最好通过开放修复还是血管内介入治疗,目前尚不清楚。本回顾性研究的目的是报告在 15 年间两个欧洲机构的开放和血管内修复的结果。我们回顾了过去 10 年发表的可用文献。
回顾了 1995 年至 2010 年间在圣玛丽医院(英国伦敦)和亨利·蒙多医院(法国克里泰)诊断出的所有 SRAAs 患者。从病历中记录了术前临床和解剖数据、手术管理和结果,并进行了分析。
共发现 40 例 51 个 SRAAs。男性 21 例,女性 19 例,平均年龄 57 ± 14.9 岁。动脉瘤的位置分别为:14 个(27%)为肾动脉,11 个(22%)为脾动脉,7 个(14%)为腹腔干,7 个(14%)为肠系膜上动脉,4 个(8%)为肝动脉,4 个(8%)为胰十二指肠弓,3 个(6%)为胃左动脉,1 个(2%)为胃十二指肠动脉。4 例患者为破裂性 SRAAs。16 例患者中有 17 个 SRAAs 接受开放修复,15 例患者中有 15 个 SRAAs 接受血管内治疗,17 个(平均直径:18mm,范围:8-75mm)接受保守治疗。1 例转移性肺癌患者,肠系膜上动脉(75mm)和腹腔干(15mm)有两个真菌性动脉瘤,予以姑息治疗。血管内治疗后,即刻技术成功率为 100%。在 30 天术后死亡率和围手术期并发症方面,开放修复和血管内患者之间无显著差异。择期治疗的患者无一例院内死亡。术后,4 例(1 例破裂,3 例择期)在开放修复组发生非致命性轻度至重度并发症,而血管内组仅 1 例(p =.34)。与血管内修复相比,开放修复的平均住院时间明显更长(17 天,范围:8-56 天 vs. 4 天,范围:2-6;p <.001)。开放修复的平均随访时间为 17.8 个月(范围:0-143 个月),血管内治疗为 15.8 个月(范围:0-121 个月),保守治疗为 24.8 个月(范围:3-64 个月)。无与 VAA 相关的迟发性死亡。在每组中,都有 2 例需要进行成功的再次手术。在血管内组中,有 2 例患者分别在 6 个月和 24 个月时出现动脉瘤囊再灌注。
在本系列中,开放修复和血管内治疗在 30 天死亡率和术后并发症发生率方面无显著差异。血管内治疗是开放修复的安全替代方法,但患者有发生动脉瘤再灌注的风险。这要求对接受血管内治疗的患者进行仔细的长期影像学随访。